KEYNOTE-042中组织肿瘤突变负荷与突变状态同临床结局的关联:帕博利珠单抗对比化疗治疗晚期PD-L1阳性非小细胞肺癌
这项Ⅲ期KEYNOTE-042试验的回顾性探索性分析评估了组织肿瘤突变负荷(tTMB)及STK11、KEAP1、KRAS突变对帕博利珠单抗单药对比铂类化疗的预测价值。793例PD-L1阳性(TPS≥1%)晚期非小细胞肺癌患者中,tTMB≥175突变/外显子者345例(43.5%)。tTMB≥175突变/外显子与帕博利珠单抗较化疗改善结局相关,而tTMB<175突变/外显子则无此关联;无论STK11、KEAP1或KRAS突变状态如何,帕博利珠单抗均为该场景的标准一线治疗。
要点
- tTMB≥175突变/外显子可能是帕博利珠单抗单药治疗PD-L1 TPS≥1%晚期NSCLC的潜在预测生物标志物。
- tTMB≥175突变/外显子组帕博利珠单抗对比化疗OS HR 0.62(95%CI 0.48-0.80),PFS HR 0.75(95%CI 0.59-0.95)。
- 帕博利珠单抗是该场景标准一线治疗,无论STK11、KEAP1或KRAS突变状态如何。
核心结论
- tTMB以≥175突变/外显子为切点可能是帕博利珠单抗单药治疗晚期/转移性PD-L1 TPS≥1% NSCLC的潜在预测生物标志物。
- 帕博利珠单抗是该场景的标准一线治疗,无论STK11、KEAP1或KRAS突变状态如何。
研究设计与样本
- Ⅲ期KEYNOTE-042试验的回顾性探索性分析,评估tTMB及STK11、KEAP1、KRAS突变与结局的关联。
- tTMB及STK11、KEAP1、KRAS突变通过肿瘤组织与配对正常DNA的全外显子测序确定。
- tTMB临床效用采用预设切点175突变/外显子评估。
- 共纳入793例PD-L1阳性(TPS≥1%)晚期/转移性NSCLC患者,无EGFR/ALK改变。
主要发现
- 793例患者中345例(43.5%)tTMB≥175突变/外显子,448例(56.5%)tTMB<175突变/外显子。
- PD-L1表达与tTMB之间未观察到关联。
- 连续tTMB评分与帕博利珠单抗组OS和PFS改善相关(Wald检验,单侧P<0.001),与化疗组无此关联(Wald检验,双侧P>0.05)。
- tTMB≥175突变/外显子组帕博利珠单抗对比化疗:OS HR 0.62(95%CI 0.48-0.80),PFS HR 0.75(95%CI 0.59-0.95)。
- tTMB<175突变/外显子组帕博利珠单抗对比化疗:OS HR 1.09(95%CI 0.88-1.36),PFS HR 1.27(95%CI 1.04-1.55)。
关键数值与推荐
- tTMB≥175突变/外显子组帕博利珠单抗对比化疗OS HR 0.62(95%CI 0.48-0.80)。
- tTMB≥175突变/外显子组帕博利珠单抗对比化疗PFS HR 0.75(95%CI 0.59-0.95)。
- tTMB<175突变/外显子组帕博利珠单抗对比化疗OS HR 1.09(95%CI 0.88-1.36)。
- tTMB<175突变/外显子组帕博利珠单抗对比化疗PFS HR 1.27(95%CI 1.04-1.55)。
- STK11突变型(n=33)帕博利珠单抗对比化疗OS HR 0.37(95%CI 0.16-0.86),STK11野生型(n=396)OS HR 0.83(95%CI 0.65-1.05)。
临床怎么用
- 帕博利珠单抗是该场景(晚期/转移性PD-L1 TPS≥1% NSCLC无EGFR/ALK改变)的标准一线治疗,无论STK11、KEAP1或KRAS突变状态如何。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated whether tissue tumor mutational burden (tTMB) and STK11, KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive (tumor proportion score ≥1%) advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations in the phase III KEYNOTE-042 trial. PATIENTS AND METHODS: This retrospective exploratory analysis assessed prevalence of tTMB and STK11, KEAP1, and KRAS mutations determined by whole-exome sequencing of tumor tissue and matched normal DNA and their associations with outcomes in KEYNOTE-042. Clinical utility of tTMB was assessed using a prespecified cut point of 175 mutations/exome. RESULTS: Of 793 patients, 345 (43.5%) had tTMB ≥175 mutations/exome and 448 (56.5%) had tTMB <175 mutations/exome. No association was observed between PD-L1 expression and tTMB. Continuous tTMB score was associated with improved overall survival (OS) and progression-free survival among patients receiving pembrolizumab (Wald test, one-sided P < 0.001) but not those receiving chemotherapy (Wald test, two-sided P > 0.05). tTMB ≥175 mutations/exome was associated with improved outcomes for pembrolizumab versus chemotherapy, whereas tTMB <175 mutations/exome was not {OS: hazard ratio, 0.62 [95% confidence interval (CI) 0.48-0.80] and 1.09 (95% CI 0.88-1.36); progression-free survival: 0.75 (0.59-0.95) and 1.27 (1.04-1.55), respectively}. Improved OS [hazard ratio (95% CI)] for pembrolizumab versus chemotherapy was observed regardless of STK11 [STK11 mutant (n = 33): 0.37 (0.16-0.86), STK11 wild-type (n = 396): 0.83 (0.65-1.05)]; KEAP1 [KEAP1 mutant (n = 64): 0.75 (0.42-1.35), KEAP1 wild-type (n = 365): 0.78 (0.61-0.99)], or KRAS [KRAS mutant (n = 69): 0.42 (0.22-0.81); KRAS wild-type (n = 232): 0.86 (0.63-1.18)] mutation status. CONCLUSION: tTMB with a cut point of ≥175 mutations/exome is a potential predictive biomarker for pembrolizumab monotherapy for advanced/metastatic PD-L1 tumor proportion score ≥1% NSCLC. Pembrolizumab is a standard first-line treatment in this setting regardless of STK11, KEAP1, or KRAS mutation status.
引用
- Mok TSK, Lopes G, Cho BC, et al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol. 2023. PMID: 36709038. doi:10.1016/j.annonc.2023.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。